Literature DB >> 21658343

Treatment-resistant depression: prevalence, risk factors, and treatment strategies.

Michael E Thase1.   

Abstract

Full symptomatic remission is the optimal outcome for patients with major depression. Unfortunately, initial antidepressant efficacy is limited to partial response for many patients. Incomplete remission of depressive symptoms is associated with increased risk of relapse, decreased functioning in work and social settings, and increased risk of suicide. Factors that increase the likelihood of treatment resistance include chronicity, severe symptomatology, and comorbid illnesses. Strategies to manage patients who do not respond to an initial course of antidepressant medication include optimizing the dose, switching antidepressants, or adding adjunctive treatment (ie, psychotherapy or a second medication). Augmentation may be the preferred strategy for improving response if tolerability to the original agent is acceptable and the initial medication has had some beneficial effects. Tracking patients' depressive symptoms with standardized measurement tools during the course of treatment is necessary for identifying incomplete remission and providing appropriate treatment modification. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658343     DOI: 10.4088/JCP.8133tx4c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

Review 2.  When she says "no" to medication: psychotherapy for antepartum depression.

Authors:  Anna R Brandon; Marlene P Freeman
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

3.  A clinical risk stratification tool for predicting treatment resistance in major depressive disorder.

Authors:  Roy H Perlis
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

Review 4.  Treatment resistant depression: A multi-scale, systems biology approach.

Authors:  Huda Akil; Joshua Gordon; Rene Hen; Jonathan Javitch; Helen Mayberg; Bruce McEwen; Michael J Meaney; Eric J Nestler
Journal:  Neurosci Biobehav Rev       Date:  2017-08-30       Impact factor: 8.989

Review 5.  Antidepressant use and new-onset diabetes: a systematic review and meta-analysis.

Authors:  Sandipan Bhattacharjee; Rituparna Bhattacharya; George A Kelley; Usha Sambamoorthi
Journal:  Diabetes Metab Res Rev       Date:  2013-05       Impact factor: 4.876

6.  Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.

Authors:  R Lanzenberger; P Baldinger; A Hahn; J Ungersboeck; M Mitterhauser; D Winkler; Z Micskei; P Stein; G Karanikas; W Wadsak; S Kasper; R Frey
Journal:  Mol Psychiatry       Date:  2012-07-03       Impact factor: 15.992

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study.

Authors:  Roger S McIntyre; Emmanuelle Weiller
Journal:  Adv Ther       Date:  2015-05-13       Impact factor: 3.845

9.  Key considerations in the pharmacological management of treatment-resistant depression.

Authors:  Mani Yavi; Ioline D Henter; Lawrence T Park; Carlos Zarate
Journal:  Expert Opin Pharmacother       Date:  2021-07-21       Impact factor: 3.889

10.  Treatment-resistant depression in primary care across Canada.

Authors:  Sakina J Rizvi; Etienne Grima; Mary Tan; Susan Rotzinger; Peter Lin; Roger S Mcintyre; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2014-07       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.